Enabling next-generation therapeutics through improved endosomal escape

Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues, such as muscle, heart, kidney and the brain.
With successful PoCs in rodents and non-human primates, Sapreme is now building a pipeline of therapeutic applications to address high unmet needs in neuromuscular, renal, cardiometabolic diseases and beyond.
Our lead program is designed as a best-in-class therapy for Duchenne muscular dystrophy, an incurable and fatal pediatric monogenic disease. In addition, we are pursuing strategic partnerships to co-develop products with select pharma/biotech companies.

Science

The problem: Less than 1% of next-generation therapeutics cross cellular barriers efficiently

Large molecules do not cross cell- or endosomal membranes efficiently. Therefore, intracellular target engagement is inefficient. This leads to limited new treatment options for patients, despite validated and promising disease targets. There is a high need for improved intracellular delivery of next-generation oligonucleotide therapeutics (siRNAs and ASOs).

 

Our solution: Harnessing the power of endosomal escape enhancers evolved in plant biology

Sapreme has selected a unique class of plant secondary metabolites (glycosylated triterpenoids) that specifically enhance delivery of large molecules to the cellular cytoplasm by mediating endosomal escape. Through advanced chemical modification of these natural compounds, Sapreme has developed a proprietary technology platform (SPT) with optimized medicinal properties. Our SPT platform selectively enhances receptor-targeted delivery to endosomes and enables pH-driven endosomal release of the therapeutic. Endosomal targeting and proprietary linker technology means that SPT remains inactive in circulation and has unprecedented endosomal escape potency and tolerability.

Team

Executive Management Team

Board of Directors

Jeanne Bolger

Jeanne Bolger

Chair
Marco Timmers

Marco Timmers

CEO
Karl Rothweiler

Karl Rothweiler

Hendrik Zonnenberg

Hendrik Zonnenberg

News & Events

Upcoming Events

BIO INTERNATIONAL CONVENTION | San Diego, CA | 3 – 6 June 2024

Sapreme’s Chief Business Officer Sijme Zeilemaker will be attending BIO 2024, San Diego in the first week of June this year. If you would like to learn more about our pipeline of targeted RNA therapeutics and endosomal escape technology to improve your RNA therapeutics, feel free to reach out to us!

Press Releases

Bilthoven, July 20, 2023

Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

Sapreme announced today the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors. Both bring a wealth of executive, business and clinical development expertise from large pharmaceutical and innovative biotech companies as Sapreme now builds upon preclinical proof of concept in several disease indications and delivery models. Read the full press release here.

 

About Sapreme:

Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues.

For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher  |  +49 89 238 877 30  |  sapreme@trophic.eu

Careers

Open applications welcome

If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76 (Main office Desk)

Address

Antonie van Leeuwenhoeklaan 9 USP Bilthoven A12-1 3721 MA Bilthoven The Netherlands